Primary Profile

YM BioSciences Inc.

YM BioSciences Inc.

YM BioSciences Inc.

400-5045 Orbitor Dr, Bldg 11
Mississauga, Ontario
L4W 4Y4

400-5045 Orbitor Dr, Bldg 11
Mississauga, Ontario
L4W 4Y4

(905) 629-9761

(905) 629-4959

Click here

YM BioSciences Inc.

YM BioSciences Inc. is a drug development company advancing three products: CYT387, a small molecule, dual inhibitor of the JAK1/JAK2 kinases; nimotuzumab, an EGFR-targeting monoclonal antibody; and CYT997, a vascular disrupting agent (VDA). CYT387 is an orally administered inhibitor of both the JAK1 and JAK2 kinases, which have been implicated in a number of immune cell disorders including myeloproliferative neoplasms and inflammatory diseases as well as certain cancers. CYT387 is currently in a 166 patient Phase I/II trial in myelofibrosis that has completed enrollment, as well as a 60 patient Phase II BID trial that is recruiting patients. Nimotuzumab is a humanized monoclonal antibody targeting EGFR with an enhanced side-effect profile over currently marketed EGFR-targeting antibodies. Nimotuzumab is being evaluated in numerous Phase II and III trials worldwide. CYT997 is an orally-available small molecule therapeutic with dual mechanisms of vascular disruption and cytotoxicity, and has completed a Phase II trial in glioblastoma multiforme. In addition to YM’s three clinical stage products, the Company has several early-stage research programs underway with candidates from its library of novel compounds identified through internal research conducted at YM BioSciences Australia.

Company Details





325410 - Pharmaceutical and Medicine Manufacturing

541710 - Research and Development in the Physical, Engineering and Life Sciences


Product / Service / Licensing

Product Name: CYT387
CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 by Dr. Andrew Wilks.

Product Name: Nimotuzumab
Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation.

Product Name: CYT997
CYT997 is a vascular disrupting agent (VDA) that has dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.

Technology Profile

Clinical Products
The company`s focus on oncology is directed towards both active
and passive immunotherapy, as well as traditional small
molecules. All of YMB`s clinical products have issued
and pending patents protecting the IP.

Market Profile


The company in-licenses products from any geographical area and
out-licenses either globally or by territory, depending on the
rights which it has acquired through its in-licensing
The company acquires product candidates and technologies from
pharmaceutical and biotechnology companies, as well as from
academic institutions. The company currently has several types
of partnerships, including joint ventures, co-development
partnerships and license agreements.
The company is focused on oncology.
Industry Sector Market Interests:

Contact Information

Nick Glover
Title: Chief Executive Officer
Area of Responsibility: Management Executive
Telephone: (905) 629-9761
Fax: (905) 629-4959

Barb Richard
Title: Admin/Exec Assistant
Area of Responsibility: Administrative Services
Telephone: (905) 361-9486